Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 07:00PM GMT
Release Date Price: $3.88
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

(technical difficulty) of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. I also have Mary Kate Davis from the team here with me. And it's my pleasure today to introduce Mark McClung, Executive Vice President and CEO of Sangamo Therapeutics.

Mark, would you like to give some opening remarks. And then after that, we can jump into the Q&A?

D. Mark McClung
Sangamo Therapeutics, Inc. - Executive VP & COO

Yes, absolutely. So first of all, Greg, Mary Kate, thanks for having us, and thank you for your interest in Sangamo Therapeutics. So these are forward-looking statements. And as usual, we refer you to the quarterly filing that was put in last week, just for your reference.

So Sangamo Therapeutics is an exciting company. Actually, it's a genomics medicine company. It's got a long history in terms of being a pioneer in genomic medicines that hopefully will give you a sense of today. We've got multiple

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot